J Immunol 2011, 186:6287–6295 PubMedCrossRef 39 Rose-John S: IL-

J Immunol 2011, 186:6287–6295.PubMedCrossRef 39. Rose-John S: IL-6 trans-signaling via the soluble IL-6 receptor: ATM Kinase Inhibitor importance for the Pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8:1237–1247.PubMedCentralPubMedCrossRef 40. Otte J-M, Podolsky DK: Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004, 286:G613-G626.PubMedCrossRef 41. Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N: Probiotics prevent

necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 2013, 304:G132-G141.PubMedCrossRef 42. Iliev ID, Mileti E, Matteoli G, Chieppa M, Rescigno M: Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. c-Met inhibitor Mucosal Immunol 2009, 2:340–350.PubMedCrossRef 43. Rivollier A, Perrin-Cocon L, Luche S, Diemer H, Strub JM, Hanau D, van Dorsselaer A, Lotteau V, Rabourdin-Combe C, Rabilloud T, Servet-Delprat C: High expression of antioxidant proteins in dendritic cells: possible implications in atherosclerosis. Mol Cell Proteomics 2006, 5:726–736.PubMedCrossRef

44. Ballatori N, Krance SM, GDC-941 Notenboom S, Shi S, Tieu K, Hammond CL: Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009, 390:191–214.PubMedCentralPubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions DL, PB, ST and MR conceived the Carnitine palmitoyltransferase II study; MR and ST designed the study; DL, JM, PB and FN did the laboratory work; DL, JM, PB, FB, TS, ST and MR analysed the data; DL, PB, and MR wrote the manuscript; all authors read and approved the final manuscript.”
“Background Streptococcus agalactiae (Group B Streptococci – GBS) can colonize the gastrointestinal and genitourinary tracts of healthy individuals without any symptoms of disease [1]. Nevertheless, this

bacterium can cause life-threatening invasive diseases in pregnant women, neonates or non-pregnant adults. Colonized women, during pregnancy or the postpartum period, are usually asymptomatic, but GBS may cause bacteremia, urinary tract infections, chorioamnionitis, endometritis, puerperal sepsis and, occasionally meningitis and septic thrombophlebitis [2, 3]. GBS colonization among pregnant women also increases the risk of premature delivery and perinatal transmission of the microorganism to newborns, which can cause fatal sepsis and meningitis [4, 5]. A successful perinatal disease prevention strategy based on intrapartum chemoprophylaxis for pregnant women at risk [6] leads to a significant decrease in GBS infections in neonates [3, 6, 7].

Comments are closed.